Inspiremd announces abstract of one-year follow-up results from the c-guardians u.s. investigational device exemption (ide) clinical trial accepted for presentation at linc 2024

Tel aviv, israel and miami, march 26, 2024 (globe newswire) -- inspiremd, inc. (nasdaq: nspr), developer of the cguard™ embolic prevention stent system (eps) for the prevention of stroke, today announced that an abstract of the one-year outcomes from its c-guardians ide clinical trial of the cguard™ prime carotid stent system for the treatment of carotid artery stenosis has been accepted for presentation at the leipzig interventional course (linc) 2024, which is being held may 28-31, in leipzig, germany.
NSPR Ratings Summary
NSPR Quant Ranking